Prevalence of fatty liver in metabolic syndrome.
Central obesity
dyslipidemia
metabolic syndrome
non-alcoholic fatty liver disease (NAFLD)
Journal
Journal of family medicine and primary care
ISSN: 2249-4863
Titre abrégé: J Family Med Prim Care
Pays: India
ID NLM: 101610082
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
05
12
2019
revised:
16
12
2019
accepted:
07
01
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
In Western world, non-alcohlic fatty liver disease (NAFLD) is considered to be the commonest liver problem, and it is being recognised as a major cause of liver-related morbidity and mortality. As the prevalence of overweight/obesity and metabolic syndrome increases, NASH may become one of the more common causes of end stage liver disease and hepatocellular carcinoma. But much information is not available in this association. So an attempt has been made to correlate both. The aims of this study are: 1. to study the prevalence of non-alcoholic fatty liver in metabolic syndrome; and 2. to study the correlation between the non-alcoholic fatty liver and metabolic syndrome along with its individual components. The study was an observational and analytical study of patients attending OPD and indoor patients of the Department of Medicine, G.G.S. Medical College and Hospital Faridkot. In total, 100 patients diagnosed as metabolic syndrome according to the NCEP ATP III criteria were subjected to ultrasonography; age and sex matched 100 controls were also taken; and the relationship between metabolic syndrome and NAFLD was studied. In total, 73% cases of metabolic syndrome according to NCEP ATPIII were having fatty liver, while in controls 38% persons were having fatty liver which is statistically significant. Fatty liver was found to be highly prevalent in metabolic syndrome, and the early detection of fatty liver can help in modifying the disease course and delaying more serious complications like cirrhosis of liver and hepatocellular carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
In Western world, non-alcohlic fatty liver disease (NAFLD) is considered to be the commonest liver problem, and it is being recognised as a major cause of liver-related morbidity and mortality. As the prevalence of overweight/obesity and metabolic syndrome increases, NASH may become one of the more common causes of end stage liver disease and hepatocellular carcinoma. But much information is not available in this association. So an attempt has been made to correlate both.
AIMS
OBJECTIVE
The aims of this study are: 1. to study the prevalence of non-alcoholic fatty liver in metabolic syndrome; and 2. to study the correlation between the non-alcoholic fatty liver and metabolic syndrome along with its individual components.
MATERIALS AND METHODS
METHODS
The study was an observational and analytical study of patients attending OPD and indoor patients of the Department of Medicine, G.G.S. Medical College and Hospital Faridkot. In total, 100 patients diagnosed as metabolic syndrome according to the NCEP ATP III criteria were subjected to ultrasonography; age and sex matched 100 controls were also taken; and the relationship between metabolic syndrome and NAFLD was studied.
RESULTS
RESULTS
In total, 73% cases of metabolic syndrome according to NCEP ATPIII were having fatty liver, while in controls 38% persons were having fatty liver which is statistically significant.
CONCLUSIONS
CONCLUSIONS
Fatty liver was found to be highly prevalent in metabolic syndrome, and the early detection of fatty liver can help in modifying the disease course and delaying more serious complications like cirrhosis of liver and hepatocellular carcinoma.
Identifiants
pubmed: 33102278
doi: 10.4103/jfmpc.jfmpc_1108_19
pii: JFMPC-9-3246
pmc: PMC7567270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3246-3250Informations de copyright
Copyright: © 2020 Journal of Family Medicine and Primary Care.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
J Viral Hepat. 2008 Mar;15(3):165-72
pubmed: 18233989
J Assoc Physicians India. 2009 Mar;57:201-4
pubmed: 19588647
Indian J Med Res. 2009 Mar;129(3):285-92
pubmed: 19491421
World J Gastroenterol. 2007 Dec 21;13(47):6419-24
pubmed: 18081233
Dig Dis Sci. 2007 Sep;52(9):2368-74
pubmed: 17420951
Diabetes Res Clin Pract. 2009 Apr;84(1):84-91
pubmed: 19168251
World J Gastroenterol. 2006 Jun 7;12(21):3400-5
pubmed: 16733858
Hepatology. 2009 Nov;50(5):1403-11
pubmed: 19670414
BMC Gastroenterol. 2018 Jul 6;18(1):109
pubmed: 29980170
Trop Gastroenterol. 2004 Apr-Jun;25(2):76-9
pubmed: 15471321
Cureus. 2019 Feb 19;11(2):e4099
pubmed: 31057993
BMJ Open. 2014 Oct 03;4(10):e005413
pubmed: 25280803